Decreases of Mapk14 and Prkcg mRNA levels following FAAH inhibition highlights hopes for new treatment strategies of neuropathic components in rheumatic diseases, as seen with intrathecal administration of p38α MAPK and PKCγ inhibitors in a chronic constriction injury model of neuropathic pain [37,38]. This evidence concerns the gene PRKCG and rheumatic disorder.